Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more
Market Cap & Net Worth: Solvonis Therapeutics plc (SVNS)
Solvonis Therapeutics plc (LSE:SVNS) has a market capitalization of $0.27 (GBX2.23K) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #51608 globally and #1587 in its home market, demonstrating a 9.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Solvonis Therapeutics plc's stock price GBX0.25 by its total outstanding shares 9102 (9.10K).
Solvonis Therapeutics plc Market Cap History: 2025 to 2026
Solvonis Therapeutics plc's market capitalization history from 2025 to 2026. Data shows growth from $0.34 to $0.27 (0.00% CAGR).
Solvonis Therapeutics plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Solvonis Therapeutics plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SVNS by Market Capitalization
Companies near Solvonis Therapeutics plc in the global market cap rankings as of March 18, 2026.
Key companies related to Solvonis Therapeutics plc by market ranking:
- GE Vernova LLC (NYSE:GEV): Ranked #66 globally with a market cap of $227.10 Billion USD.
- Siemens Aktiengesellschaft (XETRA:SIE): Ranked #93 globally with a market cap of $175.49 Billion USD ( €170.96 Billion EUR).
- Siemens AG Class N (PINK:SMAWF): Ranked #113 globally with a market cap of $155.24 Billion USD.
- Eaton Corporation PLC (NYSE:ETN): Ranked #140 globally with a market cap of $133.05 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #66 | GE Vernova LLC | NYSE:GEV | $227.10 Billion | $844.05 |
| #93 | Siemens Aktiengesellschaft | XETRA:SIE | $175.49 Billion | €219.15 |
| #113 | Siemens AG Class N | PINK:SMAWF | $155.24 Billion | $199.00 |
| #140 | Eaton Corporation PLC | NYSE:ETN | $133.05 Billion | $363.95 |
Solvonis Therapeutics plc Historical Marketcap From 2025 to 2026
Between 2025 and today, Solvonis Therapeutics plc's market cap moved from $0.34 to $ 0.27, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX0.27 | -20.97% |
| 2025 | GBX0.34 | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Solvonis Therapeutics plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $0.27 USD |
| MoneyControl | $0.27 USD |
| MarketWatch | $0.27 USD |
| marketcap.company | $0.27 USD |
| Reuters | $0.27 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.